Combination therapy of dydrogesterone and progesterone together with folic acid in the treatment of recurrent abortion on the outcome of Re-pregnancy

This study aimed to assess the impact of combining dydrogesterone and progesterone with folic acid in the treatment of recurrent abortion on re-pregnancy outcomes. A retrospective analysis was conducted on 94 women with recurrent abortion admitted between June 2020 and July 2022. Participants were randomly assigned to a control group (treated with progesterone and folic acid) and a research group (treated with dydrogesterone, progesterone, and folic acid). Clinical effectiveness, adverse effects, serum cytokine levels, T lymphocyte subsets, endometrial parameters, and uterine artery perfusion indices were evaluated, along with pregnancy outcomes. The research group exhibited a significantly higher overall effective rate (89.36%) compared to the control group (70.21%). Both groups showed a reduction in interferon (IFN) and interleukin-6 (IL-6) levels and an increase in IL-10 levels post-treatment (P < 0.05). The research group showed higher Treg/CD4 + levels, better endometrial thickness, and fewer adverse reactions (8.51% vs. 23.40%) compared to the control group. The success rate of fetal preservation was higher in the research group (82.98%) compared to the control group (59.57%). The combination of dydrogesterone and progesterone with folic acid effectively improves the success rate of fetal preservation, modulates T lymphocyte levels, reduces inflammatory factors, and enhances endometrial receptivity, positively influencing pregnancy outcomes in cases of recurrent abortion.